GRDX · GridAI Technologies Corp. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern one year from the date these financial statements are issued. ... As a result, the Company concluded that its plans at this stage do not alleviate substantial doubt about the ability to continue as a going concern.”View the 10-Q filed Aug 21, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $36.25K | — | — | — | — | — | $0 | $0 | — | — | — | |
| — | $693.68K | — | — | — | — | — | — | — | — | — | — | |
| — | -$657.43K | — | — | — | — | — | — | — | — | — | — | |
| — | -1813.56% | — | — | — | — | — | — | — | — | — | — | |
| $1.54M | $925.48K | $903.94K | $5.03M | $8.78M | $16.99M | $5.89M | $8.68M | $5.77M | $2.4M | $2.5M | $1.4M | |
| $9.43M | $5.5M | $14.72M | $10.74M | $11.99M | $18.38M | $7.29M | $6.06M | $7.45M | $7.69M | $4.13M | $3.33M | |
| — | — | — | — | — | $528K | $528K | $780K | $736.54K | $704.48K | $690.2K | $691.82K | |
| — | $574.71K | $48.95K | $29.27K | $29K | $15K | $38K | $63.1K | — | — | — | — | |
| $21.04M | $6.43M | $15.62M | $15.77M | $12.68M | $59.06M | $26.43M | $14.74M | $13.43M | — | — | — | |
| -$22.34M | -$7.08M | -$15.62M | -$15.77M | -$12.68M | -$59.06M | -$26.43M | -$14.74M | -$13.43M | -$10.22M | -$6.33M | -$4.73M | |
| — | -19539.98% | — | — | — | — | — | — | — | — | — | — | |
| — | -$6.51M | -$15.57M | -$15.74M | -$12.65M | -$59.04M | -$26.39M | -$14.68M | — | — | — | — | |
| — | — | — | $22.46K | $15.88K | $11.24K | $5.84M | $433.94K | $101.85K | $875.2K | $5.94M | $1.59M | |
| $886 | — | — | $2531 | $8415 | $1173 | $484 | $0 | — | — | — | — | |
| $495.38K | $443.42K | $2253 | -$24.16K | -$1.95M | $519.04K | -$6.24M | — | — | — | — | — | |
| -$21.85M | -$6.64M | -$15.62M | — | — | — | -$32.67M | -$15.18M | — | -$11.1M | -$14.59M | -$5.93M | |
| — | -$398.74K | — | — | — | $0 | $0 | $0 | — | $0 | $0 | $0 | |
| -$20.61M | -$6.39M | -$18.06M | -$15.79M | -$14.63M | -$58.54M | -$32.67M | -$15.18M | -$13.53M | -$11.1M | -$14.59M | -$5.93M | |
| — | -17634.42% | — | — | — | — | — | — | — | — | — | — | |
| — | -$160.92K | — | — | — | — | — | — | — | — | — | — | |
| -$20.84M | -$6.73M | -$18.3M | -$16.1M | -$14.97M | -$84.52M | -$41.73M | -$15.18M | — | — | — | — | |
| — | — | — | -$15.79M | -$13.41M | -$58.65M | -$32.83M | -$15.29M | -$13.73M | -$10.59M | -$14.71M | -$6.53M | |
| USD/shares | -$5.92 | -$4.16 | -$15.99 | -$143.64 | -$1,250.82 | -$119,311.80 | -$184,968.00 | — | — | — | — | — |
| USD/shares | -$5.92 | -$4.16 | -$15.99 | -$143.64 | -$1,250.82 | -$119,311.80 | -$184,968.00 | — | — | — | — | — |
| shares | — | 1.62M | 1.14M | 112.11K | 11.97K | 708.3833 | 225.6848 | 0 | -0 | 84.3558 | 51.6253 | 28.7868 |
| shares | — | 1.62M | 1.14M | 112.11K | 11.97K | 708.3833 | 225.6848 | 0 | -0 | 84.3558 | 51.6253 | 28.7868 |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 248 similar-size Biotechnology companies (of 533 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 |
|---|---|
| Grid Ai Corp Segment | $36,251 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Grid Ai Corp Segment | -$2,638,060 | — | — |
| Gridai Technologies Corp Segment | -$4,445,378 | -$15,621,274 | — |
| Drug Development | — | — | -$4,869,278 |
Operating Margin by Segment (%)
| Component | FY2025 |
|---|---|
| Grid Ai Corp Segment | -7277.2% |